Nucleic Acid Therapeutics in Rare Disease: From Precision Medicine to Programmable Platforms.
- 1Genetics and Genomic Medicine Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London, UK.
- 2NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK.
Abstract
Nucleic acid therapeutics (NATs), including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), messenger RNA (mRNA) therapeutics and programmable editing technologies, are reshaping the therapeutic landscape for inherited metabolic and genetic disease. Unlike conventional small molecules or biologics, NATs enable sequence-directed modulation of target gene expression and therefore provide unprecedented flexibility for targeting pathogenic mechanisms previously considered undruggable. Recent clinical successes have established proof of concept for multiple NAT modalities across neurological, hepatic, muscular and metabolic disorders. However, broader implementation remains constrained by challenges in tissue-specific delivery, biomarker validation, natural-history infrastructure and evidence generation in ultra-rare populations. In parallel, increasing platform reproducibility is beginning to challenge traditional product-based regulatory paradigms. This review examines the principal classes of NATs and proposes a practical framework for modality selection based on disease biology, tissue accessibility, durability, reversibility and clinical context. We discuss key translational bottlenecks beyond delivery, including biomarker-outcome relationships, small-population trial design and the limitations of conventional evidentiary frameworks in rare disease. A central theme of this review is the growing transition from isolated precision medicines towards increasingly programmable therapeutic platforms. We explore how advances in extrahepatic delivery, computational oligonucleotide design, artificial intelligence-assisted optimisation and programmable editing technologies may progressively support more scalable and individualised therapeutic development. Finally, we discuss emerging regulatory frameworks that may better accommodate platform-level predictability while maintaining rigorous evaluation of sequence-specific and disease-specific risks.
Related
- Exosomes in regenerative medicine from biological messengers to engineered nanocarriers for precision therapeutics
- PDGFRα-directed fibroblast-homing peptides for targeted delivery of nucleic acid therapeutics
- Pharmaceutical Applications of Nucleic Acid Aptamers: Recent Advances and Future Perspectives in Therapeutics, Biosensing, Bioanalysis, and Process Analysis
- Programmable and sustainable scaling up of squaramide-based compounds through customizable paper-based platforms.
- AI-integrated RNA therapeutics in precision oncology
BibTeX
@article{tomkiewicz2026nucleic,
title = {{Nucleic Acid Therapeutics in Rare Disease: From Precision Medicine to Programmable Platforms.}},
author = {Tomasz Z Tomkiewicz and Siyamini Sivananthan and Paul Gissen and Haiyan Zhou},
journal = {Journal of inherited metabolic disease},
year = {2026},
month = nov,
doi = {10.1002/jimd.70262},
url = {https://europepmc.org/article/MED/42972926},
note = {CC BY},
}
RIS
TY - JOUR
TI - Nucleic Acid Therapeutics in Rare Disease: From Precision Medicine to Programmable Platforms.
AU - Tomasz Z Tomkiewicz
AU - Siyamini Sivananthan
AU - Paul Gissen
AU - Haiyan Zhou
PY - 2026
DA - 2026/11/01
JO - Journal of inherited metabolic disease
DO - 10.1002/jimd.70262
UR - https://europepmc.org/article/MED/42972926
AB - Nucleic acid therapeutics (NATs), including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), messenger RNA (mRNA) therapeutics and programmable editing technologies, are reshaping the therapeutic landscape for inherited metabolic and genetic disease. Unlike conventional small molecules or biologics, NATs enable sequence-directed modulation of target gene expression and therefore provide unprecedented flexibility for targeting pathogenic mechanisms previously considered undruggable. Recent clinical successes have established proof of concept for multiple NAT modalities across neurological, hepatic, muscular and metabolic disorders. However, broader implementation remains constrained by challenges in tissue-specific delivery, biomarker validation, natural-history infrastructure and evidence generation in ultra-rare populations. In parallel, increasing platform reproducibility is beginning to challenge traditional product-based regulatory paradigms. This review examines the principal classes of NATs and proposes a practical framework for modality selection based on disease biology, tissue accessibility, durability, reversibility and clinical context. We discuss key translational bottlenecks beyond delivery, including biomarker-outcome relationships, small-population trial design and the limitations of conventional evidentiary frameworks in rare disease. A central theme of this review is the growing transition from isolated precision medicines towards increasingly programmable therapeutic platforms. We explore how advances in extrahepatic delivery, computational oligonucleotide design, artificial intelligence-assisted optimisation and programmable editing technologies may progressively support more scalable and individualised therapeutic development. Finally, we discuss emerging regulatory frameworks that may better accommodate platform-level predictability while maintaining rigorous evaluation of sequence-specific and disease-specific risks.
SN - 0141-8955
SN - 1573-2665
ER -